Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders PCSK9 inhibitors may be effective treatment for PAD PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS

Bo Angelin Articles

PCSK9 and the adrenals: how are cholesterol levels protected?

Reports from the 9th Closed Expert Meeting of the PCSK9 Education and Research Forum Professor Bo Angelin

Posted on 9 November 2018 | Posted by Bo Angelin | Posted in Webcasts, 9th Closed Scientific Expert Meeting of the Editorial Board

How does PCSK9 inhibition influence cholesterol metabolism in humans?

In the absence of clear evidence, Professor Bo Angelin, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden discusses what might be expected from the acute and long-term effects of PCSK9 inhibition.

Posted on 25 May 2016 | Posted by Bo Angelin | Posted in Webcasts, 4th Closed Scientific Expert Meeting of the Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters